JAZZ
Companies
NASDAQ
Jazz Pharmaceuticals plc
Health Care
$108.24
-$15.54 (-12.62%)
Price Chart
Overview
About JAZZ
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Market Cap
$7.1B
Volume
163.0M
Avg. Volume
145.7M
P/E Ratio
4.9990726
Dividend Yield
0.00%
Employees
3.0K
Company Information
Latest News for JAZZ
Risk & Correlation Analysis
Market Correlation
0.55
Low Correlation
Volatility
Medium (0.27)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, JAZZ shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$7.1B
Volume163.0M
P/E Ratio5.00
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
February 26, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025